On Tuesday, Becton Dickinson expressed confidence in the ability of its COVID-19 tests to detect the novel coronavirus strain Omicron.
COVID-19 testing, including antigen and PCR tests, are available from the firm. It began selling at-home quick COVID-19 testing in the United States in October, with results confirmed using a fully automated smartphone app.
Becton further stated that all accessible genome sequences from the Global Initiative on Sharing All Influenza Data (GISAID) — the world's biggest library of new coronavirus genome sequences — were used to analyze the variant.
According to the business, it has analyzed millions of genomes so far and found no undetected changes.
It makes the disclosure a day after Thermo Fisher Scientific confirmed that its diagnostic tests can detect the Omicron version accurately.
The World Health Organization (WHO) categorized the Omicron variety as a SARS-CoV-2 "variant of concern," last week, warning that it could spread faster than other strains.